Dashboard

Transgene (Euronext: TNG),

part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.

The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.

Stock

Loading…
Stock quote

Corporate Presentation (June 2017)

Corporate Presentation

Press Releases

Receive email alerts

Financial Calendar


Financial Information


Key figures

In € million
except share and per share data
2016 2015 2014 2013 2012
Revenue 10.3 9.9 11.1 15.7 13.1
R&D Expense -26.4 -32.1 -41.7 -50.1 -48.7
G&A Expense -6.2 -5.8 -7.6 -6.8 -6.6
Net Loss -25.2 -46.4 -48.6 -42.9 -43.2
Net Cash Burn -30.6 -34.8 -44.9 -45.0 -46.6
Cash & Cash Equivalents 56.2 31.6 65.9 47.9 92.9
Loss per Share (Basic and Diluted) -0.45 -1.20 -1.26 -1.34 -1.36
Shares Outstanding 56,431,991 38,545,397 38,527,968 31,874,858 31,762,134


Financial Reports

Years Quarters First
Half
Registration
Document
Annual
Report
First Second Third Fourth
2017  
2016            
2015              
2014            
2013            
2012              
2011              
2010              
2009            
2008            
2007          *  

* Available in French only


Regulated Information

Interim Financial Reports

Quarterly Reports

Rights issue (October-November 2016)

Chairman’s report on corporate governance and internal controls

Auditors’ Fees

Monthly information on shares outstanding and voting rights (French only)

Share buyback program (French only)

Liquidity contract related information (French only)

Half-Year Report on the Transgene Liquidity Contract

Offering memorandum or prospectus (as appropriate)

None

Annual General Meeting information

Stock Information


General

Stock Market Euronext Paris – Eurolist (compartment B)
Reuters / Bloomberg TRNG.PA / TNG.FP
ISIN Code FR0005175080
Total number of shares outstanding 56,431,991
Initial Public Offering (IPO) March 26, 1998
Local Sector Index Next Biotech / CAC Mid 100
Financial Year Ends December 31


Stock Price

Loading…
Stock quote



Shareholder structure

graph shareholder structure

Analysts

Company Analyst E-mail Phone
Bryan Garnier & Co. Ltd Mickael Chane-Du mchanedu@bryangarnier.com +33 (0)1 70 36 57 45
Edison Investment Juan Pedro R. Serrate jpserrate@edisongroup.com +44 (0)20 3077 5700
+44 (0)20 3681 2534
Invest Securities Martial Descoutures mdescoutures@invest-securities.com +33 (0)1 44 88 88 09
Kempen & Co. Suzanne van Voorthuizen suzanne.vanVoorthuizen@kempen.com +31 (0)20 348 8484
Kepler Cheuvreux Thomas Guillot tguillot@keplercheuvreux.com +33 1 70 98 85 27
Life Science Capital LLC Adam Evertts aevertts@lifescicapital.com +1 646 597-6997
Natixis Jean-Jacques Le Fur jeanjacques.lefur@natixis.com +33 (0)1 58 55 05 13
Oddo BHF Pierre Corby pcorby@oddo.fr +33 (0)1 44 51 85 00

Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.


Investor Events & Presentations


Financial Calendar



Investor Events

  • January 5, 2017 - Oddo Forum: January 5 & 6, 2017 – Lyon, France
  • January 6, 2017 - Biotech Showcase (concurrent with the J.P. Morgan 35th Healthcare Conference): January 9 to 11, 2017 – San Francisco, USA
  • January 26, 2017 - Biomed Event: January 26, 2017 – Paris, France
  • February 1, 2017 - Lond Capital Mid Small Cap Forum: February 1 & 2, 2017 – Zurich, Switzerland
  • March 13, 2017 - Exane BNP Paribas 19th Healthcare Conference: March 13 & 14, 2017 – Paris, France
  • April 19, 2017 - Kempen 10th Life Sciences Conference: April 19, 2017 – Amsterdam, Netherlands
  • June 9, 2017 - Kepler Biotech Days: June 9, 2017 – Paris, France
  • June 22, 2017 - R&D Day (in English): June 22, 2017 – Paris, France

Corporate Governance

Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and accepted by regulators as guidance for best governance practices.

 

Board of Directors

The Board of Directors is currently composed of ten members, elected for renewable three-year terms. Six members of the Board are independent directors as defined in the Code. The Board is chaired by the Chairman and Chief Executive Officer. The Board has adopted a charter of internal regulations that governs the conduct of the Board of Directors and its committees. Detailed information can be found in the Registration Document.

The Board of Directors is assisted by two committees:

The Audit Committee is composed of four directors of the Board, three of whom are independent. The Vice President Finance is invited to attend each Committee meeting to present the financial situation of the Company. The Audit Committee’s operations are governed by a charter that is reviewed regularly. The committee regularly reports on its work and provides recommendations to the Board of Directors.

The Compensation Committee is composed of two independent directors and is responsible for recommending to the Board of Directors the salaries, bonuses and share-based compensation to executives and key personnel of the Company.

 

Management Committee

The Management Committee is a non-statutory body that oversees the Company’s daily operations and ensures, in all managerial aspects, that the Company’s strategy is properly executed in accordance with its objectives. The committee is composed of nine members

The Company has established a number of other internal bodies and procedures, for example, for financial controlling, project management and risk management.

Annual General Meeting

Annual General Meeting of June 8, 2017
ORDINARY AND EXTRAORDINARY MEETING

Location
TRANSGENE
400 boulevard Gonthier d’Andernach – Parc d’Innovation
67400 ILLKIRCH-GRAFFENSTADEN – FRANCE

Date and Time
8 June 2017 at 10am

Documents